Publication

Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer.

Paniwnyk, Z.
Teesdale-Spittle, P.H.
Plumb, J.A.
Willmore, E.
Austin, C.A.
Patterson, Laurence H.
Publication Date
2003
End of Embargo
Supervisor
Rights
Peer-Reviewed
Yes
Open Access status
closedAccess
Accepted for publication
Institution
Department
Awarded
Embargo end date
Additional title
Abstract
Chloroethylaminoanthraquinones are described with intercalating and alkylating capacity that potentially covalently cross-link topoisomerase II (topo II) to DNA. These compounds have potent cytotoxic activity (IC(50) = 0.9-7.6 nM) against the A2780 human ovarian carcinoma cell line. Hydroxyethylaminoanthraquinones also reported in this paper have similar IC(50) values (0.7-1.7 nM) in the same cell line. Alchemix (ZP281M, 1-(2-[N,N-bis(2-chloroethyl)amino]ethylamino)-4-(2-[N,N-(dimethyl)amino]ethylamino)-5,8-dihydroxy-9,10-anthracenedione), an alkylating anthraquinone, retains excellent antitumor activity in Adriamycin-resistant (2780AD) and cisplatin-resistant (2780/cp70) cell lines in vitro and in vivo. This indicates that Alchemix can evade both P-glycoprotein efflux pump and DNA mismatch repair-mediated resistance. In treated cells, Alchemix was shown to preferentially induce drug-stabilized covalent bound topo IIalpha-DNA complexes over topo IIbeta-DNA complexes.
Version
No full-text in the repository
Citation
Pors, K., Paniwnyk, Z., Teesdale-Spittle, P., Plumb, J.A. and Patterson, L.H. (2003). Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer. Molecular Cancer Therapeutics. Vol 2, No. 7, pp. 607-610.
Link to publisher’s version
Link to Version of Record
Type
Article
Qualification name
Notes

Version History

Now showing 1 - 2 of 2
VersionDateSummary
2*
2025-04-08 11:43:54
Editing author name
2009-10-20 13:47:42
* Selected version